Oppenheimer analyst Mohan Naidu views the sell-off in Evolent Health (NYSE: EVH) is overdone and overshadows upcoming opportunities. The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Evolent Health (EVH) PT Lowered to $21 at Oppenheimer Following 4Q February 27, 2019 9:42 AM